Equity research analysts covering C4 Therapeutics, Inc. (NASDAQ: CCCC) maintain an overwhelmingly positive consensus, with ratings pointing toward a Strong Buy based on clinical progress in targeted protein degradation therapies. However, clinical-stage biotechnology equities carry high binary risks. What is your specific risk tolerance, investment horizon, and target asset allocation? Consulting a licensed financial advisor is recommended before executing trades.